AzTrials
AzTrials

Peripheral Artery DiseasesNCT04625660

Detour2 Continued Access Study

A study testing PQ Bypass System in people with Peripheral Artery Diseases, run by Endologix at 3 sites in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

Prospective, single-arm, multi-center, clinical investigation to continue to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass. Read more about this study

Who is it for?
Ages 18 to 90 years
Conditions the study is for
Peripheral Artery Diseases
What is being tested?
PQ Bypass System
Type of treatment
Medical device
Could I receive a placebo?
No, everyone receives an active treatment
How many people
11 participants
Where
3 sitesUnited States
Study dates
7 Apr 2021to 14 May 2024
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 18 to 90 years
  • All sexes
  • No healthy volunteers
  • Adult, Older adult

General Inclusion Criteria

  1. Age > 18 and ≤ 90 years of age.
  2. Willing and able to provide informed consent.
  3. Subject is willing to undergo all follow-up assessments according to the specified schedule over 24 months. Clinical Inclusion Criteria
  4. Chronic, symptomatic lower limb ischemia defined as Rutherford clinical categories 3, 4, or 5.
  5. Venous Clinical Severity Score < 3.
  6. Subject is a suitable candidate for angiography and endovascular intervention and, if required, is eligible for standard surgical repair. Angiographic Inclusion Criteria
  7. Symptomatic femoropopliteal chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or Symptomatic femoropopliteal lesions ≥ 24 cm (total lesion length) that can include a chronic total occlusion or a
  • 70% lesion that includes de novo, restenotic or in-stent restenosis, by investigator visual assessment.
  1. Reference vessel diameter ≥ 4.5 and ≤ 6.7 mm, by investigator visual assessment.
  2. Subject has a patent popliteal artery (<50% stenosis) distal to the landing zone
  3. Able to successfully access the SFA origin for entry of the crossing device.
  4. At least one patent infrapopliteal vessel (<50% stenosis) with run-off to the ankle or foot.
  5. A significant stenosis (≥ 50%) or occlusion of an ipsilateral, inflow artery (e.g. aortoiliac, common femoral) must be successfully treated (use of investigational treatment prohibited) prior to treatment of the target lesion. Successful treatment is defined as no complications and less than 30% residual stenosis following intervention.

General Exclusion Criteria

  1. Participating in another investigational clinical study that has not reached the study endpoint or interferes with endpoints of this study
  2. Anticipated life expectancy less than 1 year or medical comorbid condition(s) that could limit the subject's ability to comply with the requirements of the trial.
  3. Subject has other medical, social or psychological problems that, in the opinion of the investigator, preclude them from receiving this treatment, and the procedures and evaluations pre- and post-treatment. Clinical Exclusion Criteria
  4. History of deep vein thrombosis the target limb.
  5. Thrombophlebitis, within the previous 30 days.
  6. Planned or previous major amputation of the target limb.
  7. Known or suspected active infection at the time of the procedure (e.g., WIfI foot infection grade 3: Severe infection. Local infection with systemic inflammatory response syndrome [SIRS]).
  8. Rutherford clinical category 0, 1, 2 or 6.
  9. Has acute or chronic renal disease with GFR ≤ 30 ml/min per 1.73 m2 and/or elevated serum creatinine >2.5mg/dL (220µmol/L) or on dialysis.
  10. Known hypersensitivity/allergy to the investigational devices and/or required pharmacotherapy that cannot be safely managed.
  11. Morbid obesity that does not allow for safe vascular access, adequate imaging, or impacts to mobility.
  12. Subject has a known coagulopathy or has bleeding diatheses, thrombocytopenia with platelet count less than 100,000/microliter or INR > 1.8.
  13. Any planned vascular interventions within 14 days before and/or 30 days following the index procedure (successful inflow treatment is permitted prior to enrollment).
  14. Has a known history of intracranial bleeding or aneurysm, myocardial infarction or stroke within the last 3 months.
  15. Subject is pregnant or breast-feeding. Angiographic Exclusion Criteria
  16. Stent within 3 cm of SFA ostium.
  17. Previous bypass surgery on the target limb that would inhibit adequate crossing proximally and distally. (e.g. the SFA artery was ligated during the bypass surgery).
  18. Subject has significant disease or obstruction (≥50%) of the inflow tract that has not been successfully treated at the time of the index procedure (success measured as
  • 30% residual stenosis, without complication)
  1. Presence of aneurysm or acute thrombus in the target limb.
  2. Thrombolysis of the target vessel within 72 hours prior to the index procedure, where complete resolution of the thrombus was not achieved.

Trial locations and contacts

3 sites in 1 country.

United States3 sites
  • AMITA Medical Group

    Elk Grove Village, Illinois, 60007

  • Sentara Norfolk

    Norfolk, Virginia, 23502

  • The Vascular Experts

    Old Saybrook, Connecticut, 06475

Other trials in United States

About this study

Official title: The DETOUR2 Continued Access Clinical Trial - The Detour Endovascular Technique for Long OcclUsive Fem-pop Revascularization - Continued Access Clinical Trial

Prospective, single-arm, multi-center, clinical investigation to continue to evaluate the safety and effectiveness of the PQ Bypass System to access, deliver guidewires, and implant stent grafts for a percutaneous femoropopliteal (fem-pop) bypass.

Being tested
PQ Bypass System
Medical subject headings
Peripheral Arterial Disease

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • PQ Bypass SystemDevice

    Intended use from CLN232 Rev A (CLN232 is the DETOUR2 Continued Access Protocol) The PQ Bypass System is intended to improve blood flow in patients with peripheral arterial disease in symptomatic femoropopliteal lesions due to chronic total occlusions ≥ 20 cm that can include de novo, restenotic, or in-stent restenotic lesions; or total lesion lengths ≥24 cm that can include chronic total occlusions or a ≥70% lesion that includes de novo, restenotic or in-stent restenosis.

Study groups in NCT04625660
Study groupRoleWhat they receive
Single ArmExperimentalThe PQ Bypass system is used during a minimally invasive procedure to place stent grafts in the peripheral vasculature to improve blood flow.
Receives: Device: PQ Bypass System

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Primary Safety Endpoint at 30 Days

    Freedom from a major adverse event (MAE) at 30 days post-procedure defined as any occurrence of the following events: Death, Clinically-Driven Target Lesion Revascularization (CD-TLR), Major Amputation of the Treated Limb, Symptomatic Deep Vein Thrombosis (DVT), or Pulmonary Embolism, or procedure-related bleeding requiring any transfusion of packed red blood cells or surgery.

    Measured: 30 Days

  2. Primary Effectiveness Endpoint - Patency at 12 Months

    The absence of clinically-driven target lesion revascularization and absence of recurrent target lesion diameter stenosis >50% by imaging (e.g., duplex ultrasound peak systolic velocity ratio of >2.5 or invasive angiography) within the stent or immediately 1 cm above or below the treated segment. When both modalities are available, angiography takes precedence.

    Measured: 12 Months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted12 Nov 2020
  2. Study start7 Apr 2021
  3. Primary completion14 May 2024
  4. Study completion14 May 2024

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrolment
11 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT04625660
Sponsor's protocol ID
CLN 232
Status last verified
Mar 2024
First submitted
5 Nov 2020
Last updated
15 Oct 2024
Results posted
No
Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
Yes
Individual data sharing
No

Questions about this trial

What is this clinical trial studying?

A study testing PQ Bypass System in people with Peripheral Artery Diseases, run by Endologix at 3 sites in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 15 Oct 2024. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 3 sites in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Primary Safety Endpoint at 30 Days (time frame: 30 Days). The study lists 2 primary outcomes in all. It is what the study was designed to measure, not a finding.

Where can I read the original study information?
Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 15 Oct 2024.

Free account

Keep searching with a free account

You’ve used your 3 free searches for this session. Log in or create a free AzTrials account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in